Clinical trial

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia

NCT00253968 · Sanofi, Industry · Completed

Key facts

NCT number NCT00253968
Title Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia
Official title Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: a 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study
Acronym GEMS
Lead sponsor Sanofi, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Sleep Initiation and Maintenance Disorders, Insomnia
Intervention type Drug
Interventions Eplivanserin, placebo
Enrollment 967
Start date Nov 1, 2005
Primary completion Jan 1, 2008
Completion Jan 1, 2008
First posted Nov 15, 2005
Last update posted Mar 1, 2016
Countries Argentina, Australia, Canada, Chile, Czechia, France, Germany, Mexico, Netherlands, Spain, United Kingdom, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies